Compare Ascendis Pharma A/S (ASND) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Mondaycom Ltd — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while Mondaycom Ltd trades at $87.01 (market cap $3.54B). The key difference: Ascendis Pharma A/S is far larger — about 5× Mondaycom Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | MNDY | |
|---|---|---|
Market Cap | $17.74B | $3.54B |
Sector | Health | Technology |
52-Week High | $277.18 | $292.24 |
52-Week Low | $163.32 | $58.81 |
Enterprise Value | $18.11B | $2.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Monday.com (MNDY) trades at $82.47, down 1.41% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $116.75. The company reported strong revenue of $1.23 billion in 2025 and has beaten EPS estimates for three consecutive quarters, though its EV/EBITDA of 110.73 indicates high valuation expectations. Recent news highlights investor interest despite stock volatility, with the Motley Fool noting the dip may present a buying opportunity.
The outlook for MNDY is positive based on analyst sentiment and earnings performance, but risks include elevated valuation multiples and competitive pressures in the SaaS sector. Investors should weigh the company's robust growth against potential market volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
